Endothelial dysfunction and cardiometabolic diseases: Role of long non-coding RNAs.

  title={Endothelial dysfunction and cardiometabolic diseases: Role of long non-coding RNAs.},
  author={Hai-Jian Sun and Bao Hou and Xu Wang and Xuexue Zhu and Ke-Xue Li and Liying Qiu},
  journal={Life sciences},
Endothelial dysfunction in diabetes and hypertension: Role of microRNAs and long non‐coding RNAs
Mechanism of Long Non-Coding RNAs in Autophagy and Inflammation of Vascular Endothelial Cells: A Review
This review discusses the correlations between lncRNAs and vascular endothelia cells with emphasis on regulation of lnc RNAs on both autophagy and inflammation in vascular endothelial cells.
Extracellular Vesicle-Mediated Vascular Cell Communications in Hypertension: Mechanism Insights and Therapeutic Potential of ncRNAs
The current findings focusing on the emerging roles of extracellular vesicle-carrying ncRNAs in the pathologies of hypertension and its associated vascular remodeling are discussed and highlighted.
Epigenetic mechanisms underlying the benefits of flavonoids in cardiovascular health and diseases: are long non-coding RNAs rising stars?
Based on a review of research on the modulatory effects of lncRNAs and their roles in mediating cellular processes, flavonoids might facilitate a significant epigenetic modification as part of their tissue-/cell-related biological effects.
Role of Endothelial Dysfunction in Cardiovascular Diseases: The Link Between Inflammation and Hydrogen Sulfide
Hydrogen sulfide (H2S), an entry as a gasotransmitter, exerts diverse biological effects through acting on various targeted signaling pathways and is postulated to be a new indicator for endothelial cell inflammation and its associated endothelial dysfunction.
LncRNAs in vascular biology and disease.
Noncoding RNAs as therapeutic targets in atherosclerosis with diabetes mellitus
Recent progresses in research on functional regulatory role of ncRNAs in atherosclerosis with DM is summarized and new thoughts and findings relevant to nc RNAs as potential therapeutic targets or biomarkers for atheros sclerosis with DM are illustrated.
Long Non-coding RNAs in Vascular Health and Disease
Long noncoding RNAs (lncRNAs) play important roles in the regulation of diverse biological processes within the vessel wall in health and disease. Emerging studies have identified unique mechanisms
Can Epigenetics of Endothelial Dysfunction Represent the Key to Precision Medicine in Type 2 Diabetes Mellitus?
This review aims to summarize the most current knowledge regarding the involvement of epigenetic changes associated with endothelial dysfunction in T2DM, in order to identify potential targets that might contribute to pursuing “precision medicine” in the context of diabetic illness.
Benefits of Curcumin in the Vasculature: A Therapeutic Candidate for Vascular Remodeling in Arterial Hypertension and Pulmonary Arterial Hypertension?
The present review attempts to focus on the current findings and molecular mechanisms of curcumin in the treatment of hypertensive vascular remodeling, as well as some favorable pharmacokinetics or pharmacodynamics profiles in arterial hypertension.


lncRNA-MIAT Regulates Microvascular Dysfunction by Functioning as a Competing Endogenous RNA
To elucidate whether lncRNA-myocardial infarction–associated transcript (MIAT) is involved in diabetes mellitus–induced microvascular dysfunction, quantitative polymerase chain reaction demonstrated increased expression of lnc RNA-MIAT in diabetic retinas and endothelial cells cultured in high glucose medium.
Role of noncoding RNA in vascular remodelling
Given the important roles of ncRNAs in vascular injury and remodelling together will their capacity for cell-to-cell communication, manipulating ncRNA might provide novel therapeutic interventions.
Pathogenic role of lncRNA-MALAT1 in endothelial cell dysfunction in diabetes mellitus
It is shown that MALAT1 expression is significantly upregulated in the retinas of STZ-induced diabetic rats and db/db mice, which represents a critical pathogenic mechanism for diabetes-induced microvascular dysfunction.
Noncoding RNAs regulate NF-κB signaling to modulate blood vessel inflammation
The literature regarding the control of vascular inflammation by microRNAs is summarized, and insight into how these microRNA-based pathways might be harnessed for therapeutic treatment of disease is provided, including emerging areas of endothelial cell biology.
Reversibility of endothelial dysfunction in diabetes: role of polyphenols.
The role of polyphenolic compounds in modulating the differentially regulated pathways and thus maintaining vascular homeostasis has been proven to be beneficial.
Long noncoding RNA-MEG3 is involved in diabetes mellitus-related microvascular dysfunction.
Clinical Significance of Endothelial Dysfunction in Essential Hypertension
The clinical significance of endothelium dysfunction in essential hypertension is investigated by accumulating novel data on (a) early diagnosis using robust markers with prognostic value in cardiovascular risk prediction, (b) the association of endothelial dysfunction with subclinical vascular organ damage, and (c) potential therapeutic targets.
Prospective and therapeutic screening value of non-coding RNA as biomarkers in cardiovascular disease.
This work summarizes the existing data about ncRNA as biomarker in the whole entity of CVDs by literature-based review and comparison of the identified candidates, finding the myomirs miRNA-1, -133a/b, -208a, -499 with well-defined cellular functions have proven equal to classic protein biomarkers for disease detection in MI.
GDF-15 as a Target and Biomarker for Diabetes and Cardiovascular Diseases: A Translational Prospective
It is a challenge for the scientific community to use GDF-15 information for patient monitoring, clinical decision-making, and replacement of current treatment strategies for diabetic and cardiovascular diseases.
Vascular endothelial dysfunction and pharmacological treatment.
  • J. Su
  • Biology, Medicine
    World journal of cardiology
  • 2015
Experimental and clinical studies have demonstrated that a variety of currently used or investigational drugs, such as angiotensin-converting enzyme inhibitors, ang Elliotensin AT1 receptors blockers, angiotENSin-(1-7), antioxidants, beta-blockers, calcium channel blockers, endothelial NO synthase enhancers, phosphodiesterase 5 inhibitors, sphingosine-1-phosphate and statins, exert endothelial protective effects.